Colbeck Capital Supports World NF Awareness Day and the Children's Tumor Foundation
World NF Awareness Day takes place annually on May 17 during NF Awareness Month, a dedicated time to elevate the inspirational and remarkable stories of those living with NF, and the critical need for research to better their lives. Through dedicated events and partner initiatives around the world, the Foundation is able to raise awareness and support to help change perceptions of the condition and strive for a cure. Support from Jason Colodne and Colbeck Capital are part of a matching opportunity designed to increase donations and inspire others to help drive research, expand knowledge, and advance care for the NF community.
Founded in 1978, the Children's Tumor Foundation is the drug discovery engine for NF. CTF brings treatments to patients faster by connecting doctors, scientists, pharmaceutical partners, and affected families with a mission to end NF. Through a patient-first, collaborative approach, CTF accelerates drug development and delivers life-changing therapies to individuals living with neurofibromatosis and schwannomatosis. To learn more about the foundation, please click here.
About Colbeck Capital Management
Colbeck Capital Management (colbeck.com) is a leading, middle-market private credit manager focused on strategic lending. Colbeck originates senior secured loans to companies going through periods of transition, providing creative capital solutions. Colbeck sponsors its portfolio companies through consistent engagement with management teams in areas such as finance, capital markets and growth strategies, distinguishing itself from traditional lenders. Colbeck was founded in 2009 by Jason Colodne and Jason Beckman and currently manages $3+ billion of invested and committed capital. Colbeck's principals have extensive experience investing through different market cycles at leading institutions, including Goldman Sachs and Morgan Stanley.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?
The global pharmaceutical sector is under increasing pressure as rising trade tensions drive countries to introduce new tariffs on drug exports. These policy shifts are straining international supply chains and pushing operating costs sharply higher. At the center of this global shake-up stands Merck & Co. (MRK), a name synonymous with blue-chip dividends. With patent protection for Keytruda, which accounts for about 40% of Merck's pharma sales, set to expire in 2028, the clock is ticking for the company to chart its next growth chapter. More News from Barchart This Dividend King Just Issued a Tariff Warning. Is Its Reliable Yield Enough to Soften the Blow? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! In response, Merck has launched a bold $3 billion cost-cutting plan, even as it braces for potential tariff-driven headwinds. Can Merck's focus on cost discipline and innovation sustain its dividend legacy amid tariff shocks and patent cliffs? Let's find out. Dissecting Merck's Latest Numbers Merck & Co. (MRK) is a pharmaceutical powerhouse with a market capitalization of approximately $196.1 billion, anchored by an industry-defining oncology portfolio and expanding animal health business. Merck's $3.24 annualized dividend per share and robust 4.15% yield remain highly attractive, underpinned by a disciplined 40.41% dividend payout ratio. Backed by over a decade of growth, MRK has been a reliable choice for income investors. Shares trade down 20.3% year-to-date and 30% over the past 52 weeks. Merck is cheap at current levels, with a forward price/earnings (P/E) ratio of 8.75x, a 48% discount to the sector median, while its price-to-sales ratio of 3.03 also looks appealing. The latest earnings report, released on July 29, gave a granular snapshot of the crosscurrents facing MRK. Total worldwide sales clocked in at $15.8 billion, a 2% dip year-over-year, with CEO Robert Davis acknowledging that 'performance was in-line with our expectations,' and highlighting the company's resilience in oncology and animal health. On the bottom line, GAAP EPS came in at $1.76, with non-GAAP EPS at $2.13, including a $0.07 per share charge tied to the closure of the Hengrui Pharma license agreement. Keytruda again proved its centrality, contributing $8.0 billion in quarterly sales, up 9% year-over-year, and comprising nearly half of total pharmaceutical revenues. That strength countered dramatic weakness from Gardasil/Gardasil 9, which plunged 55% due to suspended China shipments amid soft demand, amplifying the impact of international trade volatility on results. New launch WINREVAIR offered an emerging bright spot, notching $336 million for the quarter and reaching $1 billion in cumulative sales just over a year post-approval. Animal Health delivered a standout 11% sales increase to $1.6 billion, reinforcing Merck's diversification ambitions. How Merck Plans to Reinvent Itself Merck is rolling out a $3 billion multiyear optimization plan designed to reshape its operations and drive $1.7 billion in annual cost savings by 2027. This initiative is already in motion, with a precise focus on boosting efficiencies across administrative, sales, and select R&D functions. The urgency is real, as Merck prepares for the 2028 expiration of Keytruda's US patent, a pivotal event that will expose the company to fierce biosimilar competition and pressure future cash flows. The company's swift action is evident from the $649 million restructuring charge registered this quarter alone, making it clear that Merck's leadership is committed to preemptively reinforcing the business against industry headwinds and potential market shocks. On the growth front, Merck is not content to simply trim costs. The July 2025 announcement of its planned $10 billion acquisition of Verona Pharma underscores a strategic pivot toward pipeline diversification and therapeutic innovation. Bringing Ohtuvayre, the first new inhaled COPD treatment in more than two decades and FDA approved in June 2024, into Merck's suite of assets puts Merck ahead of rivals in addressing growing global respiratory health needs. Additionally, Merck is investing in digital transformation to elevate its commercial capabilities. By deepening its partnership with Veeva Systems (VEEV) and rolling out Veeva Vault CRM, Merck is upgrading the core technology that will drive the success of upcoming product launches. What Experts Are Watching The latest earnings consensus sees the company posting $2.41 per share in the third quarter and $8.97 in earnings for the full year, representing a striking 53.5% year-over-year jump for Q3 and 17% for the fiscal year. This optimism is reflected in management's own outlook, with the company narrowing full-year revenue expectations to between $64.3 billion and $65.3 billion and pegging non-GAAP EPS between $8.87 and $8.97. Sentiment among analysts is cautiously upbeat, if not outright bullish. The 24 analysts in coverage have given MRK a 'Moderate Buy' rating overall. The mean price target stands at $103.18, suggesting an impressive 30.1% upside from recent levels. Still, not every voice on Wall Street is equally enthusiastic. Cantor Fitzgerald, for instance, recently maintained a 'Neutral' rating with an $83.00 price target, down from its former $85.00 price target, noting that while Merck's latest earnings were largely in line with expectations, the combination of narrowed guidance and a massive $3 billion restructuring program highlights the tough road ahead. Conclusion In the near term, investors should keep a sharp eye on Merck's progress with its $3 billion cost-cutting drive, the outcome of its Verona Pharma acquisition, and any updates on managing the looming Keytruda patent expiration. Cost cuts alone probably will not be a magic bullet as real upside may require successful pipeline launches and smart deal-making. If Merck executes well and avoids tariff surprises, shares could have room to rebound from current depressed levels. Still, until results show clear momentum, expect the stock to stay volatile. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
4 hours ago
- Yahoo
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings this Monday after market hours. Here's what you need to know. BioMarin Pharmaceutical beat analysts' revenue expectations by 1% last quarter, reporting revenues of $745.1 million, up 14.8% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. Is BioMarin Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting BioMarin Pharmaceutical's revenue to grow 7% year on year to $761.8 million, slowing from the 19.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.01 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BioMarin Pharmaceutical has missed Wall Street's revenue estimates twice over the last two years. Looking at BioMarin Pharmaceutical's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. BioMarin Pharmaceutical's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $96.26 (compared to the current share price of $57.75). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
The 3 Things That Matter for Pfizer Now
Key Points Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to reduce expenses should help it navigate tariff-related challenges. 10 stocks we like better than Pfizer › Once a market darling during the early pandemic years, Pfizer (NYSE: PFE) has been on a straight southbound path for several years now. The company's shares are down by 50% since 2022. Some investors might see this as an opportunity to buy the stock on the dip, but that'd only be a good move if there are excellent reasons to think the stock might bounce back. There are several things investors can watch out for to determine this. Let's consider three of the most important. 1. Pfizer's oncology pipeline Any struggling pharmaceutical company will try to turn things around by developing newer medicines. Pfizer is no exception; its pipeline is deep, with over 100 active programs. The drugmaker is particularly focused on making a significant impact in the oncology market, one of the largest segments in the industry. That's why Pfizer spent $43 billion to acquire Seagen, a smaller biotech that specialized in oncology. At the time of the acquisition, Seagen had several approved cancer drugs, but it had an especially impressive pipeline for a company of its size. Pfizer's CEO said: "We are not buying the golden eggs. We are acquiring the goose that is laying the golden eggs." The idea was that Seagen's innovative abilities, coupled with Pfizer's resources and vast experience and reach in the industry, would eventually produce even better outcomes. Pfizer has made other moves to bolster its oncology pipeline since that acquisition. Earlier this year, it signed a licensing agreement with China-based 3SBio for SSGJ-707, an investigational bispecific antibody -- a niche that is increasingly gaining ground in oncology. Pfizer's clinical and regulatory progress in this market will be crucial in the next few years. Investors should closely monitor the company's oncology-related developments. 2. The progress of newer approvals The drugmaker has earned approval for several new medicines in recent years. These include Abrysvo, a vaccine for the respiratory syncytial virus (RSV); cancer medicine Elrexfio; and Litfulo, which treats alopecia areata. Unfortunately, none of these is making significant contributions to Pfizer's top line yet. That said, they haven't been on the market for that long; all were first approved in 2023. There's still time for these newer products to make a more meaningful impact on Pfizer's financial results, especially as they gain new indications. For instance, Abrysvo recently got a label expansion in Europe, allowing it to be prescribed to lower the risk of respiratory tract disease caused by RSV in people aged 18 to 59. Litfulo is undergoing clinical trials targeting Crohn's disease, ulcerative colitis, and vitiligo. Elrexfio is also in several phase 3 studies for additional indications. Investors should check on clinical and regulatory progress for these and other newer drugs in Pfizer's arsenal. 3. Pfizer's cost-cutting efforts Pfizer has been looking to boost its bottom line by reducing expenses. The company set a cost-savings target of $4.5 billion for this year, and during the first quarter, management said it was on track to achieve that. These efforts matter for at least two reasons. First, any company -- especially one whose revenue growth is as inconsistent as Pfizer's has been in recent years -- can benefit from cutting expenses, so long as doing so doesn't hurt other aspects of its business. Second, with President Donald Trump's tariffs threatening to increase manufacturing costs for pharmaceutical companies, Pfizer's efforts could help mitigate the impact of the administration's trade policies. So, that's something else to watch out for. Is Pfizer's stock a buy? Though Pfizer has not performed well recently and will encounter some critical patent cliffs within the next few years (notably, that of its anticoagulant Eliquis), there are good reasons for long-term investors to consider the stock. One is that shares look far too cheap at current levels. The company's forward price-to-earnings ratio was recently 8.3, which is much lower than the healthcare industry's average of 16.5. Another is that the drugmaker's extensive pipeline should enable it to overcome recent challenges to revenue growth in the long run. Finally, Pfizer is also a decent dividend stock. So, despite some challenges, it's still worth serious consideration. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. The 3 Things That Matter for Pfizer Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
